Neuroaid

NeuroAiD has shown favourable outcome in patients suffering from spinal cord injuries

Retrieved on: 
Monday, June 6, 2022

Spinal cord injury (SCI) carries debilitating consequences with severe neurological and functional deficits, deteriorating the quality of life for survivors and their relatives.

Key Points: 
  • Spinal cord injury (SCI) carries debilitating consequences with severe neurological and functional deficits, deteriorating the quality of life for survivors and their relatives.
  • SATURN (Spinal cord injury Assessing Tolerability and Use of combined Rehabilitation and NeuroAiD) study was designed to evaluate the safety and potential role of NeuroAiD in subjects suffering from severe SCI.
  • NeuroAiD shows a favourable safety profile and promising benefits as an add-on therapy to patients suffering from severe spinal cord injuries.
  • Spinal cord injury assessing tolerability and use of combined rehabilitation and NeuroAiD (SATURN) study primary results of an exploratory study.

NeuroAiD has shown favourable outcome in patients suffering from spinal cord injuries

Retrieved on: 
Monday, June 6, 2022

Spinal cord injury (SCI) carries debilitating consequences with severe neurological and functional deficits, deteriorating the quality of life for survivors and their relatives.

Key Points: 
  • Spinal cord injury (SCI) carries debilitating consequences with severe neurological and functional deficits, deteriorating the quality of life for survivors and their relatives.
  • SATURN (Spinal cord injury Assessing Tolerability and Use of combined Rehabilitation and NeuroAiD) study was designed to evaluate the safety and potential role of NeuroAiD in subjects suffering from severe SCI.
  • NeuroAiD shows a favourable safety profile and promising benefits as an add-on therapy to patients suffering from severe spinal cord injuries.
  • Spinal cord injury assessing tolerability and use of combined rehabilitation and NeuroAiD (SATURN) study primary results of an exploratory study.

NeuroAiD(TM)II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression

Retrieved on: 
Thursday, January 13, 2022

Current approved treatments for AD are symptomatic and do not appear to affect disease progression.

Key Points: 
  • Current approved treatments for AD are symptomatic and do not appear to affect disease progression.
  • Treatments that could effectively slow the course of AD once it has reached the clinical stage, remain an important unmet medical need.
  • The beneficial effects of NeuroAiDII on impaired cognitive functions have already been demonstrated in traumatic brain injury5.
  • The Alzheimer's disease Therapy with NEuroaid (ATHENE) Study is the first study to assess the safety and efficacy of NeuroAiDII in mild to moderate AD patients stable on standard symptomatic treatments.

NeuroAiD(TM)II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression

Retrieved on: 
Thursday, January 13, 2022

Current approved treatments for AD are symptomatic and do not appear to affect disease progression.

Key Points: 
  • Current approved treatments for AD are symptomatic and do not appear to affect disease progression.
  • Treatments that could effectively slow the course of AD once it has reached the clinical stage, remain an important unmet medical need.
  • The beneficial effects of NeuroAiDII on impaired cognitive functions have already been demonstrated in traumatic brain injury5.
  • The Alzheimer's disease Therapy with NEuroaid (ATHENE) Study is the first study to assess the safety and efficacy of NeuroAiDII in mild to moderate AD patients stable on standard symptomatic treatments.